Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome
暂无分享,去创建一个
Shuai Zhen | Yoichiro Takahashi | Shunichi Narita | Yi-Chen Yang | Xu Li | Xu Li | Shuai Zhen | Yoichiro Takahashi | S. Narita | Yi-Chen Yang
[1] G. Murphy,et al. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.
[2] George L. Wright,et al. Location of prostate‐specific membrane antigen in the LNCaP prostate carcinoma cell line , 1997, The Prostate.
[3] B. Hicke,et al. Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.
[4] D. S. Coffey,et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.
[5] K. Strebhardt,et al. Polo-Like Kinase 1: Target and Regulator of Transcriptional Control , 2006, Cell cycle.
[6] Yong Wang,et al. Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.
[7] Andrew D. Ellington,et al. Aptamer mediated siRNA delivery , 2006, Nucleic acids research.
[8] M. Malumbres,et al. Targeting cell cycle kinases for cancer therapy. , 2007, Current medicinal chemistry.
[9] Mj Callanan,et al. Location of I , 2007 .
[10] S. Barth,et al. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. , 2008, Current cancer drug targets.
[11] John J Rossi,et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] J. McNamara,et al. Cell-specific aptamers for targeted therapies. , 2009, Methods in molecular biology.
[13] J. Rossi,et al. Aptamer-targeted RNAi for HIV-1 therapy. , 2011, Methods in molecular biology.
[14] F. Veronese,et al. The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.
[15] J. Burnett,et al. RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.
[16] J. Doudna,et al. RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.
[17] François Guillemin,et al. Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. , 2012, Current drug metabolism.
[18] John C. Burnett,et al. Current Progress of RNA Aptamer-Based Therapeutics , 2012, Front. Gene..
[19] Yongxiang Zhao,et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system , 2013, Nature Biotechnology.
[20] Jeffry D. Sander,et al. Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.
[21] Xiaoting Zhang,et al. RNA aptamers and their therapeutic and diagnostic applications. , 2013, International journal of biochemistry and molecular biology.
[22] CRISPR model building , 2013 .
[23] Luke A. Gilbert,et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.
[24] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[25] Wei Zhang,et al. Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System , 2014, Cell.
[26] Jianglin Fan,et al. Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. , 2014, Journal of molecular cell biology.
[27] Yoshimitsu Takahashi,et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. , 2014, Biochemical and biophysical research communications.
[28] Dhruv Chauhan,et al. A Genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Screen Identifies NEK7 as an Essential Component of NLRP3 Inflammasome Activation* , 2015, The Journal of Biological Chemistry.
[29] Joana A. Vidigal,et al. Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries , 2015, Nature Communications.
[30] Yu-Quan Wei,et al. Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors. , 2015, Human gene therapy.
[31] J. Fu,et al. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus , 2015, Gene Therapy.
[32] Wenyan Sun,et al. CRISPR/CAS9-Mediated Genome Editing of miRNA-155 Inhibits Proinflammatory Cytokine Production by RAW264.7 Cells , 2015, BioMed research international.
[33] R. Chiarle,et al. Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system , 2016, Nature Communications.
[34] Jennifer A. Doudna,et al. Programmable RNA Tracking in Live Cells with CRISPR/Cas9 , 2016, Cell.